StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.
Oragenics Price Performance
NYSE OGEN opened at $0.40 on Wednesday. The company has a 50 day simple moving average of $0.92 and a 200-day simple moving average of $1.26. Oragenics has a 52-week low of $0.38 and a 52-week high of $7.74. The firm has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.05 and a beta of 0.50.
Oragenics (NYSE:OGEN – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
- Five stocks we like better than Oragenics
- 3 Best Fintech Stocks for a Portfolio Boost
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- 3 Warren Buffett Stocks to Buy Now
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.